## REFERENCES


[1] Ali, T., Roberts, D. N., & Tierney, W. M. (2009). Long-term Safety Concerns with Proton Pump Inhibitors. *The American Journal of Medicine , 122*, 896-903.

[2] Avner, D. L. (2000). Clinical experience with pantoprazole in Gastroesophageal Reflux Disease Clinical Therapeutics. *22*, 1169-1185.

[3] Basak, S. C., Kumar, P. S., Manavalan, R., & Narendranath. (2002). Preparation and evaluation of enteric coated pancreatin tablets. Ind J Pharm Sci. *64*, 260-64.

[4] Bruneer, G., & Harke, U. (1994). Long-term therapy with pantoprazole in patients with peptic ulceration resistant to extended high-dose ranitidine treatment. Aliment Pharmacol Ther . *8(1)*, 59-64.

[5] Colome, L. M., Haas, S. E., & Jornada, D. S. (2007). Development of HPMC and Eudragit S100 blended microparticles containing sodium pantoprazole. Pharmazie. *62*, 361-64.

[6] Comoglu, T., Gonul, N., Dogan, A., & Basci, N. (2008). Development and In vitro evaluation of pantoprazole-loaded microspheres. Drug delivery. *15*, 295-302.

[7] Cronlein J, F. K. (2006). Characterization of Delayed Release Lansoprazole Multiparticulates: Impact of Biorelevant Dissolution Media.5th world meeting on pharmaceutics.

[8] Crotts, G., Sheth, A., Twist, J., & Ghebre-Shellassie, I. (2000). Development of an enteric coating formulation and process for tablets primarily composed of a highly water soluble, organic acid. European Journal of Pharmaceutics and Biopharmaceutics. *51*, 71-76.

[9] Davis, N. M., Farr, S. J., Kellaway, I. W., Taylor, G., & Thomas, M. (1994). A Comparison of the gastric retention of alginate containing tablet formulation with and without the inclusion of excipient calcium ions. International journal of pharmaceutics. *105 (2)*, 97-101.

[10] F. Marchetti*, T. G. (2003). Proton pump inhibitors in children. *Digestive and Liver Disease , 35*, 738–746.

[11] Fan, L. F., Du, Q., Xiang, B., Li, C. L., Bai, M., Chang, Y. Z., et al. (1996). Design and in vitro/in vivo evaluation of multi-layer film coated pellets for omeprazole. Int J Pharm. *18*, 25-33.

[12] Fukui, E., Miyamuru, N., Uemura, K., Uemura, & Kobayashi, M. (2000). Preparation of Enteric-coated timed-release press-coated tablets and evaluation of their function by in vitro and in vivo tests for colon targeting. International Journal of Pharmaceutics. *204*, 7-15.

[13] Garcia, C. V., Nudelman, N. S., Steppe, M., & Schapoval, E. E. (2008). Structural elucidation of rabeprazole sodium photodegradation products. *Journal of Pharmaceutical and Biomedical Analysis , 46*, 88–93.

[14] Garcia, C. V., Paim, C. S., Steppe, M., & Schapoval, E. E. (2006). Development and validation of a dissolution test for rabeprazole sodium in coated tablets. *Journal of Pharmaceutical and Biomedical Analysis , 41*, 833–837.

[15] Gordon, M. S., Fratis, A., Goldblum, R., Jung, D., Schwartz, K. E., & Chowhan, Z. T. (1995). In vivo and in-vitro evaluation of four different aqueous polymeric dispersions for producing an enteric coated tablet International Journal of Pharmaceutics. *115(1)*, 29-34.

[16] Hampson, F. C., Farndale, A., Strugala, V., Sykes, J., & Jolliffe. (2005). Alginate Rafts and their Characterization. *International Journal of Pharmaceutics , 294*, 137-147.

[17] Health encyclopedia diseases and conditions. http://www.healthscout.com. (n.d.).

[18] http://www.medicinenet.com/gastroesophageal_reflux_disease_gerd/article.htm. (n.d.).

[19] Hua, D., George, R., Scott, V., & Ali, R. (2008). In-vitro dissolution testing of delayed release multi-particulate systems. Controlled release society annual meeting July.

[20] Imadomi, J. M., Mcintyre, L., Bernard, L., & Fendrick, M. (2003). Step-down from multiple to single-dose proton pump inhibitors; a prospective study of patients with heartburn or acid regurgitation completely relieved with PPIs The American Journal of Gastroenterolgy. *98(9)*, 1940-1944.

[21] Kivioja, A., Linnosmaa, I., Vehvilainen, A., & Vohlonen, I. (2004). Cost minimization analysis of treatment of gastroesophageal reflux disease implications of varying holding time on conclusions European Journal of Pharmaceutical Sciences. *21*, 171-17.

[22] Mandel, K. G., Daggy, B. P., Brodie, D. A., & Jacoby, H. I. (2000). Alginate-raft formulations in the treatment of heartburn and acid reflux. Ailment pharmacological Therapeutics. *14(6)*, 669-690.

[23] Marchetti, F., Gerarduzzi, T., & Ventura, A. (2003). Proton pump inhibitors in children. *Digestive and Liver Disease , 35*, 738–746.

[24] Matsuo, M., Arimori, K., & Nakamura, C. (1996). Delayed release tablets using hydroxyl ethyl cellulose as a gel forming matrix. Int J Pharm. *138*, 225-33.

[25] Pandey, V. P., Phanindrudu, A., Manavalan, R., & Livingston, J. (2002). In vitro study on capsule formulations of omeprazole containing enteric coated granules Boll Chim Farm. *141*, 419-22.

[26] Raffin, R. P., Pohlmann, A. R., & Guterres, S. S. (2006). Preparation, characterization, and in vivo anti-ulcer evaluation of pantoprazole-loaded microparticles. Eur J Pharm and Biopharm. *63*, 198-204.

[27] Ramakrishna, N., Vishwottam, K. N., Wishu, S., Koteshwara, M., & Sureshkumar, S. (2005). High-performance liquid chromatography method for the quantification of rabeprazole in human plasma using solid-phase extraction. *Journal of Chromatography , 816*, 209–214.

[28] Ravikumar, P., Bhanuprakash, P., Muralikrishna, M., Yadav, S. M., & Deepthi, A. C. (2006). Simultaneous Estimation of domperidone and pantoprazole in solid dosage form by UV spectrophotometry. *3(12)*, 142-145.

[29] Reddy, G. M., Bhaskar, V. B., Reddy, P. P., Sudhakar, P., Mosesbabu, J., Vyas, K., et al. (2007). Identification and characterization of potential impurities of rabeprazole sodium. *Journal of Pharmaceutical and Biomedical Analysis , 43*, 1262–1269.

[30] Rena, S., Park, M. J., Sha, H. B., & Lee, B. J. (2007). Effect of pharmaceutical excipients on aqueous stability of rabeprazole sodium. *National Research Laboratory for Bioavailability Control, College of Pharmacy, Kangwon National University, Chuncheon South Korea b College of Pharmacy, Ewha Womans University.*

[31] Saini, V. (2009). Antiulcer activity of pantoprazole from multiple-unit tablet dosage form. Int J PharmTech Res. *1(4)*, 1092-1093.

[32] Torkoglu, M., Varol, H., & Celikok, M. (2004). Tableting and stability evaluation of enteric-coated omeprazole pellets. European Journal of Pharmaceutics and Biopharmaceutics. *57*, 279-286.

[33] Waterhouse, E. T. (2000). Clive Washington and Neena Washington An investigation into the efficacy of the pectin based anti-reflux formulation Aflurax. International Journal of Pharmaceutics. *209 (1-2)*, 79-85.